Knowledge Hub

Follow the Money: The Outlook for Outsourced Spending on Early Development Services

Press Release   •   Jun 07, 2017 02:57 EDT

Latest industry research report on: Follow the Money Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs. Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in getting clinical trial materials needed for studies.

According to this latest report, "PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services", the driver of this early development activity has been the huge level of external funding flowing into emerging bio/pharma companies from venture capitalists and public markets. However, external funding for bio/pharma has always been a boom or bust proposition, and the likelihood that funding will be cut drastically always lurks on the horizon. This makes it difficult for CDMOs and CROs to pull the trigger on investments in new capacity.

Download Sample copy of this Report at :


- Follow the Money: The Outlook for Outsourced Spending on Early Development Services exams the link between external funding sources and early drug development, and addresses the outlook for continued funding over the next two years.

Reasons to buy

This report provides important insight that you wont find in any other source. This report is required reading for -

- CDMOs and CROs: market trends, capital investment decision-making, strategic planning, performance benchmarking

- Bio/pharma: supplier performance benchmarking, market trends, competitive intelligence

- Private equity: investment targeting, portfolio company performance benchmarking

Table of Contents

1 Table of Contents

Executive Summary 1

Context and Objectives 2

Clinical Trial Activity of Emerging Bio/Pharma Companies 4

Clinical Development Costs and Spending by Emerging Bio/Pharma Companies 7

External Financing for Emerging Bio/Pharma Companies 9

Outlook and What it Means 15

Appendix A 18

Appendix B 19

1.1 List of Tables

Table 1 2016 Performance of Drug Development Service Providers

Table 2 Profile of Emerging Bio/Pharma IPOs 2014-2015

1.2 List of Figures

Figure 1 Breakdown of Phase I and Phase II Trials by Primary Sponsor, H1 2012-H1 2016

Figure 2 Operating Expenditure of US Emerging Biopharma Companies Pre- and Post-IPO

Figure 3 Operating Expenditure of US Emerging Biopharma Companies Pre- and Post-SPO

Figure 4 Estimated Cost of Getting Candidates Through Clinical Trial Phases

Figure 5 Ownership of Emerging Bio/Pharma Companies Sponsoring Clinical Trials H1 2016

Figure 6 Equity Funding to Emerging Bio/Pharma 2010-2016

Figure 7 Venture Capital Investment in Bio/Pharma Companies

Figure 8 VC Funding to Emerging Bio/Pharma 2010-2015

Figure 9 NASDAQ Biotech Index January 13-December 2016

Figure 10 R&D Spend and Cash Runway for US Emerging Bio/Pharma Companies

Figure 11 Revenue as a Funding Source for US Emerging BioPharma

Figure 12 Proportion of Companies with > 2 Years Cash or Increasing Cash Reserves

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074